Paper des Monats
01.03.2019 March 2019: Evaluation of sCAIX as predictive marker for efficacy of neoadjuvant bevacizumab
A translational research study performed with samples obtained from a cohort of patients with HER2-negative breast cancer enrolled in the neoadjuvant GeparQuinto (GBG 44) trial has been published in the International Journey of Cancer.
01.02.2019 February 2019: Results of the GeparOcto trial
We are delighted to inform you that the results of the GeparOcto phase III study designed to compare a sequential dose-dense, dose-intensified (idd) ETC (epirubicin, paclitaxel, cyclophosphamide) with weekly PM(Cb) (paclitaxel, liposomal doxorubicin, carboplatin) for neoadjuvant treatment of patients with high-risk early breast cancer have been published in the European Journal of Cancer.
17.12.2018 Results of an interim analysis from KATHERINE trial
We are delighted to inform you that the results of an interim analysis from KATHERINE, a phase III open-labeled trial, have been published in the New England Journal of Medicine.
30.11.2018 November 2018: Exploratory analysis on obese breast cancer patients from the PANTHER trial
Further results from the prospective PANTHER trial focused on obese breast cancer patients treated with adjuvant tailored dose-dense chemotherapy versus standard treatment have been published in the Annals of Oncology.
05.11.2018 October 2018: Long-term survival analysis of GeparSixto trial
The survival analysis of patients with triple-negative and HER2-positive early breast cancer enrolled in the neoadjuvant GeparSixto (GBG 66) phase II trial have been published in the Annals of Oncology.